Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MPO | P05164 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7145521 | 0.98 | MTNR1A (0.56) | MTNR1AMTNR1BCA2MPOHTR2A | |
| SCHEMBL5234280 | 0.90 | MTNR1A (0.55) | MTNR1AMTNR1BCA2MPOHTR2A | |
| SCHEMBL8587322 | 0.86 | HTR2A (0.49) | MTNR1AMTNR1BCA2MPOHTR2A | |
| SCHEMBL4605763 | 0.86 | CYP2A6 (0.64) | MTNR1AMTNR1BCA2MPOHTR2A | |
| SCHEMBL8435339 | 0.83 | MTNR1A (0.61) | MTNR1AMTNR1BCA2MPOCYP2A6 | |
| SCHEMBL27628031 | 0.83 | MTNR1A (0.57) | MTNR1AMTNR1BCA2CYP2A6MAPT | |
| SCHEMBL8591649 | 0.82 | CYP2A6 (0.50) | MTNR1AMTNR1BCA2CYP2A6HTR5A | |
| SCHEMBL8648779 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1BCA2MPOCYP2A6 | |
| SCHEMBL8435459 | 0.80 | MTNR1A (0.58) | MTNR1AMTNR1BCA2MPOCYP2A6 | |
| SCHEMBL6985740 | 0.80 | MTNR1A (0.55) | MTNR1AMTNR1BCA2MPOCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678644-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Yidi Biotechnology Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024213089-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海壹迪生物技术有限公司 | 2024-10-17 | — | — | WO | disclosed |
| CN-108264509-B | Substituted benzothieno [2,3-c ] tetrahydropyridine derivatives, preparation method and application thereof | 复旦大学 | 2021-05-04 | — | — | CN | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| CN-103108871-A | 17a-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2013-05-15 | — | — | CN | disclosed |
| WO-1998027984-A1 | METHOD OF PRODUCING ANALGESIA BY ADMINISTRATION OF 1,2,3,4-TETRAHYDROBENZO-[b]THIENO[2,3-c]PYRIDINE AND DERIVATIVES | NEUREX CORPORATION (US) | 1998-07-02 | — | — | WO | disclosed |
| US-4971974-A | ANOREXIGENIC AGENTS, BENZO B!THIENO 2,3-C!PYRIDINE COMPOUNDS | NEUREX CORPORATION (US) | 1990-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | MTNR1A 910/4885MTNR1B 1131/4885CA2 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.